| Title | Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. | | Author(s) | Bolton C, Stone M, Edwards P, Duckers J, Evans W, Shale Dj | | Institution | Department of Respiratory Medicine, School of Medicine, Cardiff University, Academic Centre, University Hospital Llandough, Penlan Road, Penarth. Vale of Glamorgan CF64 2XX. UK . boltonce@cf.ac.uk. | | Source | Chron Respir Dis 2009; 6(2):81-7. | | Abstract | Matrix metalloproteinase-9 (MMP-9) has been implicated in airways injury in chronic obstructive pulmonary disease (COPD). Osteoporosis is common in patients with COPD, and MMP-9 is an indicator of activated osteoclasts. We hypothesized that circulating MMP-9 would be related to bone mineral density (BMD) in COPD. We explored the relationship between MMP-9, tissue inhibitors of metalloproteinases (TIMP)-1 and -2, and BMD status in patients with COPD. A total of 70 clinically stable patients with confirmed COPD and 39 control subjects underwent spirometry, dual-energy x-ray absorptiometry to determine BMD, and venous sampling for measurement of cytokines and MMP-9 and TIMP-1 and -2. In patients, circulating MMP-9 was increased: mean (SD) 38.5 (2.2) compared with control subjects 20.1 (2.0) ng/mL, P < 0.001, whereas TIMP-1 and -2 were not different. In the patients, MMP-9 was greater in those with osteoporosis, compared with those with osteopenia, no bone disease or control subjects, and patients with osteopenia had greater MMP-9 than control subjects. The adjusted receiver operating characteristics curve area for MMP-9 detecting osteoporosis was 0.86. Patients had elevated systemic inflammatory mediators compared with control subjects, but these were unrelated to bone status. Increased circulating MMP-9 in patients with COPD was related to the presence of osteoporosis and not to lung function. MMP-9 may be a biomarker of increased bone resorption. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19411568 |
|
